Muscle-invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Muscle-invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) [Phase 3]
Phase 3 NIAGARA-2 trial evaluates perioperative durvalumab with neoadjuvant ddMVAC or gemcitabine/cisplatin in muscle-invasive bladder cance…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial [Phase 2]
Phase 2 BRIGHT trial combines immunotherapy with radiation therapy to potentially avoid bladder removal after shrinking muscle-invasive blad…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 trial compares chemotherapy alone versus chemotherapy plus nivolumab or nivolumab with BMS-986205, followed by continued nivolumab…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder [Phase 2]
Phase 2 clinical trial evaluating enfortumab vedotin in combination with pembrolizumab for muscle-invasive bladder cancer to help preserve t…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]
Phase 3 trial evaluating durvalumab + tremelimumab + enfortumab vedotin versus durvalumab + enfortumab vedotin in cisplatin-ineligible or ci…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder [Phase 3]
Phase 3 study evaluating TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive bladder cancer; the …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
A ClinicalTrials.gov entry describes a study evaluating the immune-stromal landscape in muscle-invasive bladder cancer, sponsored by Assiut …
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study [Phase 3]
A Phase 3 trial (ARCHER) compares shorter-duration radiation therapy plus standard chemotherapy to standard radiation therapy with chemother…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Pembrolizumab in Muscle-invasive Bladder Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab for muscle-invasive bladder cancer and urothelial carcinoma is currently active but not re…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy [Phase 3]
This Phase 3 trial evaluates atezolizumab versus placebo as adjuvant therapy in high-risk muscle-invasive bladder cancer patients who are ct…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC [Phase 2]
A Phase 2 clinical trial is evaluating probiotics combined with targeted therapy and immunotherapy in a bladder-preserving approach for musc…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer [Phase 2]
A Phase 2 clinical trial evaluating preoperative immunotherapy combined with sacituzumab govitecan for muscle-invasive bladder cancer is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial [Phase 2]
Phase 2 trial update for a neoadjuvant intravesical therapy combining nadofaragene firadenovec with gemcitabine, cisplatin, and durvalumab i…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach [NA]
A clinical trial update on an individualized, conventionally fractionated adaptive radiation therapy approach for bladder cancer, with the s…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer [Phase 2]
Phase 2 clinical trial evaluating sacituzumab govitecan before radical cystectomy for non-urothelial muscle invasive bladder cancer; recruit…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
This clinical trial explores how neoadjuvant therapy reshapes the MHC-related immune microenvironment in muscle-invasive bladder cancer.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of enfortumab vedotin and pembrolizumab with a selective bladder-sparing approach for mu…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating enfortumab vedotin plus pembrolizumab with radiotherapy for muscle-invasive bladder cancer, cu…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy [Phase 2]
A Phase 2 clinical trial evaluating partial cystectomy with extended pelvic lymph node dissection and standard perioperative systemic therap…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy [NA]
A clinical trial at Thomas Jefferson University is evaluating postoperative outcomes of ureteral stent use versus stent-free radical cystect…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer [NA]
A clinical trial update describing a study comparing radical cystectomy versus radiochemotherapy as the preferred treatment approach for mus…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology [Phase 2]
Phase 2 clinical trial evaluating bladder-preserving approaches for muscle-invasive bladder cancer with variant histology; currently recruit…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer [Phase 2]
A Phase 2 clinical trial from the Canadian Cancer Trials Group is evaluating trimodality therapy with or without durvalumab for muscle-invas…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC [Phase 2]
A Phase 2 clinical trial update evaluating intravesical recombinant Bacillus Calmette-Guérin (BCG) followed by perioperative chemo-immunothe…